The survival advantage of IDH-mutant astrocytomas over their IDH wild-type counterparts has been also documented in several other reports [16••, 17], and WHO grade II and III astrocytic tumors with IDH mutation were found to have identical age at presentation and minimal difference in survival [17]. Here, IDH2 is linked to astrocytoma (excluding glioblastoma).